Evidence map›Paper›PMID 25866324›Full record

ArticleGynecologic oncology2015

Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates.

John B Liao, Yuen Yee Yip, Elizabeth M Swisher, Kathy Agnew, Karl Erik Hellstrom, Ingegerd Hellstrom

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
5.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

John B LiaoDepartment of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA.
Yuen Yee YipDepartment of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA.
Elizabeth M SwisherDepartment of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA.
Kathy AgnewDepartment of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA.
Karl Erik HellstromDepartment of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA.
Ingegerd HellstromDepartment of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA. Electronic address: ihellstr@u.washington.edu.
University of Washington · US

Funding

WOMEN'S REPRODUCTIVE HEALTH RESEARCH CAREER DEVELOPMENTK12HD001264 · NICHD · UNIVERSITY OF WASHINGTON · PI Barbara Ann Goff · 1998 to 2026
$8.6M
Mesothelin as biomarker and therapeutic targetR01CA134487 · NCI · UNIVERSITY OF WASHINGTON · PI HELLSTROM, INGEGERD E · 2008 to 2011
$1.3M
NCI NIH HHS 1R01CA1344867-01NCI NIH HHS R01 CA134487NICHD NIH HHS 5K12HD001264-12NICHD NIH HHS K12 HD001264
6 · The paper itself

Abstract

objectivesTo measure HE4 levels in urine from normal donors, patients with LMP tumors and ovarian cancer patients and to correlate levels with clinical factors in ovarian cancer patients.

methodsArchived samples from controls, patients with LMP tumors and ovarian cancer were tested using commercial assays, including serially collected serum and urine samples from women treated for stage III/IV serous ovarian cancer.

resultsFive of 6 patients with stage I/II and 26 of 36 stage III/IV serous ovarian cancer patients had HE4-positive urines, similar to serum samples (4 of 5 stage I/II and 26 of 34 stage III/IV) when tested at the same level of specificity (95%). Urine HE4 was more sensitive in LMP tumors: 9 of 32 urines (28%) HE4-positive versus 3 of 68 sera (4.4%, p=0.002). Mean levels of serum CA125 and HE4 decreased comparably in patients during initial treatment regardless of their primary platinum response, but mean urine HE4 levels decreased only 7% in primary platinum resistant patients while decreasing 68% in those who were sensitive. By 7months after diagnosis, urine HE4 levels were higher in primary platinum resistant patients compared to those who proved to be sensitive (p=0.051) and persisted 12months after diagnosis (p=0.014). HE4 values in urine also became positive in advance of clinical recurrence in several women while serum HE4 and serum CA-125 remained normal.

conclusionsMeasuring HE4 in urine complements serum assays for the detection of ovarian cancer and may allow identification of patients at high risk for primary platinum resistance.

Indexed as

Biomarkers, TumorCarcinoma, Ovarian EpithelialCase-Control StudiesFemaleHumansMiddle AgedNeoplasms, Glandular and EpithelialOvarian NeoplasmsProteinsWAP Four-Disulfide Core Domain Protein 2Biomarkers, TumorProteinsWAP Four-Disulfide Core Domain Protein 2WFDC2 protein, humanELISAHE4LMPOvarian cancerUrine

Identifiers

PMID25866324
PMCPMC4447602
OpenAlexW1999431506

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.